-
1
-
-
84925649961
-
-
[1] Webster, D.P., Klenerman, P., Dusheiko, G.M., et al. Lancet 385 (2015), 1124–1135.
-
(2015)
Lancet
, vol.385
, pp. 1124-1135
-
-
Webster, D.P.1
Klenerman, P.2
Dusheiko, G.M.3
-
2
-
-
84945534889
-
Extrahepatic morbidity and mortality of chronic hepatitis C
-
[2] Negro, F., Forton, D., Craxì, A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
-
(2015)
Gastroenterology
, vol.149
, pp. 1345-1360
-
-
Negro, F.1
Forton, D.2
Craxì, A.3
-
5
-
-
34250679750
-
Epidemiology of hepatitis C virus infection
-
[5] Alter, M.J., Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 13 (2007), 2436–2441.
-
(2007)
World Journal of Gastroenterology
, vol.13
, pp. 2436-2441
-
-
Alter, M.J.1
-
6
-
-
84921060015
-
Global distribution and prevalence of hepatitis C virus genotypes
-
[6] Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
-
(2015)
Hepatology
, vol.61
, pp. 77-87
-
-
Messina, J.P.1
Humphreys, I.2
Flaxman, A.3
-
7
-
-
84939653819
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
-
[7] AASLD/IDSA Guidance Panel, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
-
(2015)
Hepatology
, vol.62
, pp. 932-954
-
-
AASLD/IDSA Guidance Panel1
-
8
-
-
84931560807
-
Recommendations on treatment of hepatitis C 2015
-
[8] EASL, Recommendations on treatment of hepatitis C 2015. Journal of Hepatology 63 (2015), 199–236.
-
(2015)
Journal of Hepatology
, vol.63
, pp. 199-236
-
-
EASL1
-
9
-
-
84986582659
-
Documento di indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammessi alla rimborsabilità in Italia
-
[accessed February 2016].
-
[9] AISF. Documento di indirizzo dell'Associazione Italiana per lo Studio del Fegato per l'uso razionale di antivirali diretti di seconda generazione nelle categorie di pazienti affetti da epatite C cronica ammessi alla rimborsabilità in Italia. http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2015.aspx [accessed February 2016].
-
-
-
AISF1
-
10
-
-
84942021358
-
Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response
-
[10] Simmons, B., Saleem, J., Heath, K., et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clinical Infectious Diseases 61 (2015), 730–740.
-
(2015)
Clinical Infectious Diseases
, vol.61
, pp. 730-740
-
-
Simmons, B.1
Saleem, J.2
Heath, K.3
-
11
-
-
84896492970
-
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
-
[11] Hsu, Y.-C., Lin, J.-T., Ho, H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 59 (2014), 1293–1302.
-
(2014)
Hepatology
, vol.59
, pp. 1293-1302
-
-
Hsu, Y.-C.1
Lin, J.-T.2
Ho, H.J.3
-
12
-
-
63349097919
-
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
-
[12] Arase, Y., Suzuki, F., Suzuki, Y., et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49 (2009), 739–744.
-
(2009)
Hepatology
, vol.49
, pp. 739-744
-
-
Arase, Y.1
Suzuki, F.2
Suzuki, Y.3
-
13
-
-
84922360592
-
Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
-
[13] Hsu, Y.C., Ho, H.J., Huang, Y.T., et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 64 (2015), 495–503.
-
(2015)
Gut
, vol.64
, pp. 495-503
-
-
Hsu, Y.C.1
Ho, H.J.2
Huang, Y.T.3
-
14
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
[14] van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
-
15
-
-
79957497436
-
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C
-
[15] Backus, L.I., Boothroyd, D.B., Phillips, B.R., et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clinical Gastroenterology and Hepatology 9 (2011), 509–516.
-
(2011)
Clinical Gastroenterology and Hepatology
, vol.9
, pp. 509-516
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
-
16
-
-
77952704228
-
Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
-
[16] Bruno, S., Crosignani, A., Facciotto, C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
-
(2010)
Hepatology
, vol.51
, pp. 2069-2076
-
-
Bruno, S.1
Crosignani, A.2
Facciotto, C.3
-
17
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
-
[17] Bruno, S., Stroffolini, T., Colombo, M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
-
18
-
-
80052441244
-
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy
-
[18] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antiviral Therapy 16 (2011), 677–684.
-
(2011)
Antiviral Therapy
, vol.16
, pp. 677-684
-
-
D'Ambrosio, R.1
Aghemo, A.2
Rumi, M.G.3
-
19
-
-
84864367149
-
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
-
[19] D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
-
(2012)
Hepatology
, vol.56
, pp. 532-543
-
-
D'Ambrosio, R.1
Aghemo, A.2
Rumi, M.G.3
-
20
-
-
84877795646
-
Sustained virological response: a milestone in the treatment of chronic hepatitis C
-
[20] Morisco, F., Granata, R., Stroffolini, T., et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World Journal of Gastroenterology 19 (2013), 2793–2798.
-
(2013)
World Journal of Gastroenterology
, vol.19
, pp. 2793-2798
-
-
Morisco, F.1
Granata, R.2
Stroffolini, T.3
-
21
-
-
84952837740
-
Is the benefit of treating patients with cirrhosis proven?
-
[21] Bruno, S., Boccaccio, V., Russo, M.L., et al. Is the benefit of treating patients with cirrhosis proven?. Liver International 36 (2016), S21–S27.
-
(2016)
Liver International
, vol.36
, pp. S21-S27
-
-
Bruno, S.1
Boccaccio, V.2
Russo, M.L.3
-
22
-
-
84959559169
-
All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study
-
[Epub ahead of print]
-
[22] Leroy, V., Angus, P.W., Bronowicki, J.P., et al. All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. Hepatology, 2016, 10.1002/hep.28473 [Epub ahead of print].
-
(2016)
Hepatology
-
-
Leroy, V.1
Angus, P.W.2
Bronowicki, J.P.3
-
23
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
[23] Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New England Journal of Medicine 370 (2014), 1973–1982.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
24
-
-
84933181270
-
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis
-
[24] Reddy, K.R., Bourlière, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
-
(2015)
Hepatology
, vol.62
, pp. 79-86
-
-
Reddy, K.R.1
Bourlière, M.2
Sulkowski, M.3
-
25
-
-
84979066379
-
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)
-
[Epub ahead of print]
-
[25] Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology, 2015, 10.1002/hep.28422 [Epub ahead of print].
-
(2015)
Hepatology
-
-
Lawitz, E.1
Matusow, G.2
DeJesus, E.3
-
26
-
-
84961718490
-
-
[26] Hèzode, C., De Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program Hepatology, 62(Suppl. 1), 2015, 315A.
-
(2015)
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program Hepatology
, vol.62
, pp. 315A
-
-
Hèzode, C.1
De Ledinghen, V.2
Fontaine, H.3
-
27
-
-
77949514845
-
Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice
-
[27] Chevaliez, S., Bouvier-Alias, M., Brillet, R., et al. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE, 4, 2009, e8209.
-
(2009)
PLoS ONE
, vol.4
, pp. e8209
-
-
Chevaliez, S.1
Bouvier-Alias, M.2
Brillet, R.3
-
28
-
-
84936817310
-
Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
-
[Epub ahead of print]
-
[28] Ceccherini Silberstein, F., Di Maio, V.C., Aragri, M., et al. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology, 2015, 10.1002/hep.27895 [Epub ahead of print].
-
(2015)
Hepatology
-
-
Ceccherini Silberstein, F.1
Di Maio, V.C.2
Aragri, M.3
-
29
-
-
69949182408
-
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C
-
[29] Bochud, P.Y., Cai, T., Overbeck, K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology 51 (2009), 655–666.
-
(2009)
Journal of Hepatology
, vol.51
, pp. 655-666
-
-
Bochud, P.Y.1
Cai, T.2
Overbeck, K.3
-
30
-
-
84900992889
-
Sofosbuvir and ribavirin in HCV genotypes 2 and 3
-
[30] Zeuzem, S., Dusheiko, G.M., Salupere, R., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New England Journal of Medicine 370 (2014), 1993–2001.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1993-2001
-
-
Zeuzem, S.1
Dusheiko, G.M.2
Salupere, R.3
-
31
-
-
84943558459
-
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection
-
[31] Foster, G., Pianko, S., Brown, A., et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
-
(2015)
Gastroenterology
, vol.149
, pp. 1462-1470
-
-
Foster, G.1
Pianko, S.2
Brown, A.3
-
32
-
-
84925364974
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
-
[32] Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61 (2015), 1127–1135.
-
(2015)
Hepatology
, vol.61
, pp. 1127-1135
-
-
Nelson, D.R.1
Cooper, J.N.2
Lalezari, J.P.3
-
33
-
-
84961718490
-
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program
-
[33] Hèzode, C., et al., De Ledinghen, V., Fontaine, H., et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology, 62(Suppl. 1), 2015, 315A.
-
(2015)
Hepatology
, vol.62
, pp. 315A
-
-
Hèzode, C.1
De Ledinghen, V.2
Fontaine, H.3
-
34
-
-
84954399628
-
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
-
[34] Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology 64 (2016), 486–504.
-
(2016)
Journal of Hepatology
, vol.64
, pp. 486-504
-
-
Sarrazin, C.1
-
35
-
-
84986628244
-
Abstract from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Berlin 26–28th June
-
[35] Nelson, D.R., Abstract from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), Berlin 26–28th June. 2015.
-
(2015)
-
-
Nelson, D.R.1
-
36
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
[36] Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. New England Journal of Medicine 370 (2014), 1983–1992.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
-
37
-
-
84904647749
-
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
-
[37] Andreone, P., Colombo, M.G., Enejosa, J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147 (2014), 359–365.
-
(2014)
Gastroenterology
, vol.147
, pp. 359-365
-
-
Andreone, P.1
Colombo, M.G.2
Enejosa, J.V.3
-
38
-
-
84991085939
-
FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
-
[38] FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm.
-
-
-
-
39
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
[39] Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1889–1898.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
-
40
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
[40] Afdhal, N., Reddy, K.R., Nelson, D.R., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England Journal of Medicine 370 (2014), 1483–1493.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
-
41
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
[41] Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine 370 (2014), 1879–1888.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
-
42
-
-
84979953208
-
Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational Study
-
[42] Terrault, N., Zeuzem, S., Di Bisceglie, A.M., et al. Treatment outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational Study. Hepatology, 62(Suppl. 1), 2015, 256A.
-
(2015)
Hepatology
, vol.62
, pp. 256A
-
-
Terrault, N.1
Zeuzem, S.2
Di Bisceglie, A.M.3
-
43
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
[43] Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New England Journal of Medicine 370 (2014), 211–221.
-
(2014)
New England Journal of Medicine
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
-
44
-
-
84936845723
-
Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study
-
[44] Poordad, F., Shiff, E.R., Vierling, J.M., et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. Journal of Hepatology 62 (2015), S261–S262.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S261-S262
-
-
Poordad, F.1
Shiff, E.R.2
Vierling, J.M.3
-
45
-
-
84986588416
-
Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection
-
[45] Jacobson, I.M., Asante-Appiah, E., Wong, P., et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of Elbasvir/Grazoprevir (EBR/GZR) against GT1a Infection. Hepatology, 62, 2015, 1393A.
-
(2015)
Hepatology
, vol.62
, pp. 1393A
-
-
Jacobson, I.M.1
Asante-Appiah, E.2
Wong, P.3
-
46
-
-
85002451771
-
A phase 3 double-blind placebo-controlled evaluation of Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in naïve and experienced Genotype 1, 2, 4, 5, 6 HCV infected patients with and without cirrhosis: results of the ASTRAL-1 study
-
[46] Feld, J.J., Agarwal, K., Hezode, C., et al. A phase 3 double-blind placebo-controlled evaluation of Sofosbuvir/Velpatasvir fixed dose combination for 12 weeks in naïve and experienced Genotype 1, 2, 4, 5, 6 HCV infected patients with and without cirrhosis: results of the ASTRAL-1 study. Hepatology, 62, 2015, 1379A.
-
(2015)
Hepatology
, vol.62
, pp. 1379A
-
-
Feld, J.J.1
Agarwal, K.2
Hezode, C.3
-
47
-
-
84952931354
-
Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis
-
[47] Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. New England Journal of Medicine 373 (2015), 2618–2628.
-
(2015)
New England Journal of Medicine
, vol.373
, pp. 2618-2628
-
-
Curry, M.P.1
O'Leary, J.G.2
Bzowej, N.3
-
48
-
-
84877265572
-
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study
-
[48] Kirk, G.D., Mehta, S.H., Astemborski, J., et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Annals of Internal Medicine 158 (2013), 658–666.
-
(2013)
Annals of Internal Medicine
, vol.158
, pp. 658-666
-
-
Kirk, G.D.1
Mehta, S.H.2
Astemborski, J.3
-
49
-
-
84896509055
-
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study
-
[49] Lo Re, V., Kallan, M.J., Tate, J.P., et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of Internal Medicine 160 (2014), 369–377.
-
(2014)
Annals of Internal Medicine
, vol.160
, pp. 369-377
-
-
Lo Re, V.1
Kallan, M.J.2
Tate, J.P.3
-
50
-
-
84913598185
-
Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2
-
[50] Pircher, J., Czermak, T., Merkle, M., et al. Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2. PLoS ONE, 9, 2014, e113351.
-
(2014)
PLoS ONE
, vol.9
, pp. e113351
-
-
Pircher, J.1
Czermak, T.2
Merkle, M.3
-
51
-
-
84866379288
-
All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection
-
[51] Hernando, V., Perez-Cachafeiro, S., Lewden, C., et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. Journal of Hepatology 57 (2012), 743–751.
-
(2012)
Journal of Hepatology
, vol.57
, pp. 743-751
-
-
Hernando, V.1
Perez-Cachafeiro, S.2
Lewden, C.3
-
52
-
-
84939824828
-
Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1
-
[52] Naggie, S., Cooper, C., Saag, M., et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 705–713.
-
(2015)
New England Journal of Medicine
, vol.373
, pp. 705-713
-
-
Naggie, S.1
Cooper, C.2
Saag, M.3
-
53
-
-
84925428093
-
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial
-
[53] Sulkowski, M.S., Eron, J.J., Wyles, D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313 (2015), 1223–1231.
-
(2015)
JAMA
, vol.313
, pp. 1223-1231
-
-
Sulkowski, M.S.1
Eron, J.J.2
Wyles, D.3
-
54
-
-
84939833091
-
Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1
-
[54] Wyles, D.L., Ruane, P.J., Sulkowski, M.S., et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. New England Journal of Medicine 373 (2015), 714–725.
-
(2015)
New England Journal of Medicine
, vol.373
, pp. 714-725
-
-
Wyles, D.L.1
Ruane, P.J.2
Sulkowski, M.S.3
-
55
-
-
84862572786
-
Impact of hepatitis C co-infection on response to antiretroviral treatment
-
[55] Pulido, F., Hill, A., van Delft, Y., et al. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Reviews 14 (2012), 124–131.
-
(2012)
AIDS Reviews
, vol.14
, pp. 124-131
-
-
Pulido, F.1
Hill, A.2
van Delft, Y.3
-
56
-
-
58649101395
-
Treatment of HBV/HCV coinfection: releasing the enemy within
-
[56] Gordon, S.C., Sherman, K.E., Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology 136 (2009), 393–396.
-
(2009)
Gastroenterology
, vol.136
, pp. 393-396
-
-
Gordon, S.C.1
Sherman, K.E.2
-
57
-
-
84984585800
-
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
-
[57] Liu, C.J., Chuang, W.L., Lee, C.M., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136 (2009), 496–504.
-
(2009)
Gastroenterology
, vol.136
, pp. 496-504
-
-
Liu, C.J.1
Chuang, W.L.2
Lee, C.M.3
-
58
-
-
84945917920
-
Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection
-
[Epub ahead of print]
-
[58] Takayama, H., Sato, T., Ikeda, F., et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatology Research, 2015, 10.1111/hepr.12578 [Epub ahead of print].
-
(2015)
Hepatology Research
-
-
Takayama, H.1
Sato, T.2
Ikeda, F.3
-
59
-
-
84943328235
-
Virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir
-
[59] Collins, J.M., Raphael, K.L., Terry, C., et al. Virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clinical Infectious Diseases 61 (2015), 1304–1306.
-
(2015)
Clinical Infectious Diseases
, vol.61
, pp. 1304-1306
-
-
Collins, J.M.1
Raphael, K.L.2
Terry, C.3
-
60
-
-
84919342750
-
Extrahepatic manifestations of chronic hepatitis C virus infection
-
[60] Cacoub, P., Gragnani, L., Comarmond, C., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Digestive and Liver Disease 46:Suppl. 5 (2014), S165–S173.
-
(2014)
Digestive and Liver Disease
, vol.46
, pp. S165-S173
-
-
Cacoub, P.1
Gragnani, L.2
Comarmond, C.3
-
61
-
-
33845968066
-
For the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach
-
[61] Zignego, A.L., Ferri, C., Pileri, S.A., et al. For the Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and Liver Disease 39 (2007), 2–17.
-
(2007)
Digestive and Liver Disease
, vol.39
, pp. 2-17
-
-
Zignego, A.L.1
Ferri, C.2
Pileri, S.A.3
-
62
-
-
85014612062
-
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study
-
[Epub ahead of print]
-
[62] Saadoun, D., Thibault, V., Si Ahmed, S.N., et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Annals of the Rheumatic Diseases, 2015 [Epub ahead of print].
-
(2015)
Annals of the Rheumatic Diseases
-
-
Saadoun, D.1
Thibault, V.2
Si Ahmed, S.N.3
-
63
-
-
84923037678
-
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study
-
[63] Michot, J.M., Canioni, D., Driss, H., et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. American Journal of Hematology 90 (2015), 197–203.
-
(2015)
American Journal of Hematology
, vol.90
, pp. 197-203
-
-
Michot, J.M.1
Canioni, D.2
Driss, H.3
-
64
-
-
85020275293
-
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study
-
[Epub ahead of print]
-
[64] Gragnani, L., Piluso, A., Urraro, T., et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Current Drug Targets, 2016 [Epub ahead of print].
-
(2016)
Current Drug Targets
-
-
Gragnani, L.1
Piluso, A.2
Urraro, T.3
-
65
-
-
84938953785
-
Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease
-
[65] Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and Sofosbuvir plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
-
(2015)
Gastroenterology
, vol.149
, pp. 649-659
-
-
Charlton, M.1
Everson, G.T.2
Flamm, S.L.3
-
66
-
-
84976260348
-
Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial
-
[Epub ahead of print]
-
[66] Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and Sofosbuvir plus Ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial. Lancet Infectious Diseases, 2016, 10.1016/S1473-3099(16)00052-9 [Epub ahead of print].
-
(2016)
Lancet Infectious Diseases
-
-
Manns, M.1
Samuel, D.2
Gane, E.J.3
-
67
-
-
84962847001
-
Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
-
[in press]
-
[67] Foster, G., Irving, W., Cheung, M.C.M., et al. Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 2016, 10.1016/j.jhep.2016.01.029 [in press].
-
(2016)
Journal of Hepatology
-
-
Foster, G.1
Irving, W.2
Cheung, M.C.M.3
-
68
-
-
84939255617
-
All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience
-
[68] Reddy, R., Lim, J.K., Kuo, A., et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. Journal of Hepatology, 62, 2015, S193.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S193
-
-
Reddy, R.1
Lim, J.K.2
Kuo, A.3
-
69
-
-
84932650978
-
Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis
-
[69] Saxena, V., Nyberg, L., Pauly, M.P., et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology 62 (2015), 715–725.
-
(2015)
Hepatology
, vol.62
, pp. 715-725
-
-
Saxena, V.1
Nyberg, L.2
Pauly, M.P.3
-
70
-
-
84938572955
-
Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A)
-
[70] Jacobson, I.M., Poordad, F., Firpi-Morell, R., et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-salt part A). Journal of Hepatology, 62, 2015, S193.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S193
-
-
Jacobson, I.M.1
Poordad, F.2
Firpi-Morell, R.3
-
71
-
-
84922879093
-
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study
-
[71] Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107.
-
(2015)
Gastroenterology
, vol.148
, pp. 100-107
-
-
Curry, M.P.1
Forns, X.2
Chung, R.T.3
-
72
-
-
84930578857
-
Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients
-
[72] Burgess, S., Partovi, N., Yoshida, E.M., et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Annals of Pharmacotherapy 49 (2015), 674–687.
-
(2015)
Annals of Pharmacotherapy
, vol.49
, pp. 674-687
-
-
Burgess, S.1
Partovi, N.2
Yoshida, E.M.3
-
73
-
-
85012867206
-
Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection
-
[73] Fontana, R.J., Brown, R., Herzer, J., et al. Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection. Journal of Hepatology, 62, 2015, S629.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S629
-
-
Fontana, R.J.1
Brown, R.2
Herzer, J.3
-
74
-
-
84928208414
-
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation
-
[74] Forns, X., Charlton, M., Denning, J., et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 61 (2015), 1485–1494.
-
(2015)
Hepatology
, vol.61
, pp. 1485-1494
-
-
Forns, X.1
Charlton, M.2
Denning, J.3
-
75
-
-
84929582082
-
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant
-
[75] Pungpapong, S., Aqel, B., Leise, M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61 (2015), 1880–1886.
-
(2015)
Hepatology
, vol.61
, pp. 1880-1886
-
-
Pungpapong, S.1
Aqel, B.2
Leise, M.3
-
76
-
-
84919360641
-
An interferon-free antiviral regimen for HCV after liver transplantation
-
[76] Kwo, P.Y., Mantry, P.S., Coakley, E.T., et al. An interferon-free antiviral regimen for HCV after liver transplantation. New England Journal of Medicine 371 (2014), 2375–2382.
-
(2014)
New England Journal of Medicine
, vol.371
, pp. 2375-2382
-
-
Kwo, P.Y.1
Mantry, P.S.2
Coakley, E.T.3
-
77
-
-
84922879130
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation
-
[77] Charlton, M., Gane, E., Manns, M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148 (2015), 108–117.
-
(2015)
Gastroenterology
, vol.148
, pp. 108-117
-
-
Charlton, M.1
Gane, E.2
Manns, M.P.3
-
78
-
-
84920941109
-
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late
-
[78] Pellicelli, A.M., Montalbano, M., Lionetti, R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and Liver Disease 46 (2014), 923–927.
-
(2014)
Digestive and Liver Disease
, vol.46
, pp. 923-927
-
-
Pellicelli, A.M.1
Montalbano, M.2
Lionetti, R.3
-
79
-
-
84939271310
-
The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV
-
[79] Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV. Journal of Hepatology, 62, 2015, S620.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S620
-
-
Sarrazin, C.1
Dvory-Sobol, H.2
Svarovskaia, E.S.3
-
80
-
-
84986583915
-
Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis
-
[80] McPhee, F., Hernandez, D., Zhou, N., et al. Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis. Hepatology, 62(Suppl. 1), 2015, 560A.
-
(2015)
Hepatology
, vol.62
, pp. 560A
-
-
McPhee, F.1
Hernandez, D.2
Zhou, N.3
-
81
-
-
84941917709
-
Hepatitis C virus drug resistance – associated substitutions: state of the art summary
-
[81] Lontok, E., Harrington, P., Howe, A., et al. Hepatitis C virus drug resistance – associated substitutions: state of the art summary. Hepatology 62 (2015), 1623–1632.
-
(2015)
Hepatology
, vol.62
, pp. 1623-1632
-
-
Lontok, E.1
Harrington, P.2
Howe, A.3
-
82
-
-
84986576843
-
Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for retreatment
-
[Abstract AISF 2016]
-
[82] Di Maio, V.C., Cento, V., Di Paolo, D., et al. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for retreatment. DLD, 48(Suppl. 2), 2016, 10.106/j.dld.2015.12.022 [Abstract AISF 2016].
-
(2016)
DLD
, vol.48
-
-
Di Maio, V.C.1
Cento, V.2
Di Paolo, D.3
-
83
-
-
84940942461
-
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir
-
[83] Krishnan, P., Tripathi, R., Schnell, G., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir. Antimicrobial Agents and Chemotherapy 59 (2015), 5445–5454.
-
(2015)
Antimicrobial Agents and Chemotherapy
, vol.59
, pp. 5445-5454
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
-
84
-
-
84986568748
-
The emergence of NS5B Resistant associated variant S282T after Sofosbuvir-based treatment
-
[84] Gane, E.J., Abergel, A., Metivier, S., et al. The emergence of NS5B Resistant associated variant S282T after Sofosbuvir-based treatment. Hepatology, 62, 2015, S322A.
-
(2015)
Hepatology
, vol.62
, pp. S322A
-
-
Gane, E.J.1
Abergel, A.2
Metivier, S.3
-
85
-
-
84913603634
-
Retreatment of relapsers to Sofosbuvir/Ribavirin with Sofosbuvir/Ledipasvir: complete and rapid virologic suppression by week 4
-
[85] Osinusi, A., Marti, M., Townsend, K., et al. Retreatment of relapsers to Sofosbuvir/Ribavirin with Sofosbuvir/Ledipasvir: complete and rapid virologic suppression by week 4. Journal of Hepatology, 60, 2014, S56.
-
(2014)
Journal of Hepatology
, vol.60
, pp. S56
-
-
Osinusi, A.1
Marti, M.2
Townsend, K.3
-
86
-
-
84929600780
-
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
-
[86] Wyles, D., Pockros, P., Morelli, G., et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 61 (2015), 1793–1797.
-
(2015)
Hepatology
, vol.61
, pp. 1793-1797
-
-
Wyles, D.1
Pockros, P.2
Morelli, G.3
-
87
-
-
84927798764
-
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
-
[87] Lenz, O., Verbinnen, T., Fevery, B., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of Hepatology 62 (2015), 1008–1014.
-
(2015)
Journal of Hepatology
, vol.62
, pp. 1008-1014
-
-
Lenz, O.1
Verbinnen, T.2
Fevery, B.3
-
88
-
-
84957899900
-
Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-Ritonavir and Ombitasvir
-
[88] Krishnan, P., Schnell, G., Tripathi, R., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy 60 (2015), 1106–1113.
-
(2015)
Antimicrobial Agents and Chemotherapy
, vol.60
, pp. 1106-1113
-
-
Krishnan, P.1
Schnell, G.2
Tripathi, R.3
-
89
-
-
84939260843
-
Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-Worthy study
-
[89] Black, S., Pak, I., Ingravallo, P., et al. Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: the C-Worthy study. Journal of Hepatology 62 (2015), S677–S678.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S677-S678
-
-
Black, S.1
Pak, I.2
Ingravallo, P.3
-
90
-
-
85073892854
-
Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
-
[90] Di Maio, V.C., Armenia, D., Bellocchi, M.C., et al. Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing. Journal of Hepatology, 62, 2015, S688.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S688
-
-
Di Maio, V.C.1
Armenia, D.2
Bellocchi, M.C.3
-
91
-
-
84964762607
-
Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
-
[91] Dvory-Sobol, H., Wyles, D., Ouyang, W., et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Journal of Hepatology, 62, 2015, S221.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S221
-
-
Dvory-Sobol, H.1
Wyles, D.2
Ouyang, W.3
-
92
-
-
84876246624
-
Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir
-
[92] Wang, C., Sun, J.H., O'Boyle, D.R., et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrobial Agents and Chemotherapy 57 (2013), 2054–2065.
-
(2013)
Antimicrobial Agents and Chemotherapy
, vol.57
, pp. 2054-2065
-
-
Wang, C.1
Sun, J.H.2
O'Boyle, D.R.3
-
93
-
-
84896460675
-
Hepatitis C virus NS5A inhibitors and drug resistance mutations
-
[93] Nakamoto, S., Kanda, T., Wu, S., et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World Journal of Gastroenterology 20 (2014), 2902–2912.
-
(2014)
World Journal of Gastroenterology
, vol.20
, pp. 2902-2912
-
-
Nakamoto, S.1
Kanda, T.2
Wu, S.3
-
94
-
-
84939256727
-
Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
-
[94] Lawitz, E., Flamm, S., Yang, J.C., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Journal of Hepatology, 62, 2015, S192.
-
(2015)
Journal of Hepatology
, vol.62
, pp. S192
-
-
Lawitz, E.1
Flamm, S.2
Yang, J.C.3
-
95
-
-
84968808058
-
Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen
-
[95] Hezode, C., Chevaliez, S., Scoazec, G., et al. Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor-containing regimen. Hepatology, 62(Suppl. 2), 2015, 763A.
-
(2015)
Hepatology
, vol.62
, pp. 763A
-
-
Hezode, C.1
Chevaliez, S.2
Scoazec, G.3
-
96
-
-
84950981068
-
Results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
-
[96] Lawitz, E., Poordad, F., Gutierrez, J.A., et al. Results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease. Hepatology, 62(Suppl. 1), 2015, S227A.
-
(2015)
Hepatology
, vol.62
, pp. S227A
-
-
Lawitz, E.1
Poordad, F.2
Gutierrez, J.A.3
-
97
-
-
84979087007
-
Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir
-
[97] Poordad, F., Bennett, M., Sepe, T.E., et al. Retreatment of HCV Genotype 1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir. Hepatology, 62(Suppl. 1), 2015, 1392A.
-
(2015)
Hepatology
, vol.62
, pp. 1392A
-
-
Poordad, F.1
Bennett, M.2
Sepe, T.E.3
|